<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02157831</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 10904</org_study_id>
    <nct_id>NCT02157831</nct_id>
  </id_info>
  <brief_title>Redosing With CP-870, 893 in Patients With Clinical Benefit After a Single Infusion From A Phase I, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors</brief_title>
  <official_title>Redosing With CP-870,893 in Patients With Clinical Benefit After a Single Infusion of CP-870,893 From A Phase I, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients who had clinical benefit following a single infusion of CP-870, 893 on Protocol UPCC&#xD;
      10903 will receive a single repeated infusion of CP-870,893 at the same dose given on UPCC&#xD;
      10903 intravenously.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Subjects from UPCC 10903</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CP-870,893</intervention_name>
    <arm_group_label>Subjects from UPCC 10903</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical benefit, including stable disease, partial response, or complete response,&#xD;
             without a dose-limiting toxicity after a single infusion of CP-870,893; however,&#xD;
             patients who experienced transient, not serious, and fully reversible grade 1-3&#xD;
             increases in ALT or AST after one dose of CP-870,893 may, if otherwise eligible,&#xD;
             receive a second dose on this protocol.&#xD;
&#xD;
          -  Age at least 18 years old;&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1;&#xD;
&#xD;
          -  Adequate bone marrow function documented within 2 weeks prior to treatment, defined&#xD;
             as:&#xD;
&#xD;
          -  White blood cell (WBC) count &gt;3000 cells/μL without growth factor support;&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) ≥1500/μL without growth factor support;&#xD;
&#xD;
          -  Platelets &gt;100,000/μL without growth factor support; and&#xD;
&#xD;
          -  Hemoglobin ≥10 g/dL.&#xD;
&#xD;
          -  Adequate renal and hepatic function documented within 2 weeks prior to treatment,&#xD;
             defined as:&#xD;
&#xD;
          -  Total bilirubin &lt;1.5 times the upper limit of normal (ULN);&#xD;
&#xD;
          -  Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &lt;2.5 × ULN;&#xD;
&#xD;
          -  Creatinine clearance (CLcr, measured or calculated) &gt;80 mL/min; and&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks;&#xD;
&#xD;
          -  Signed written informed consent.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Concurrent treatment with any anticancer agent;&#xD;
&#xD;
          -  History of autoimmune disorder, including pemphigus vulgaris, systemic mastocytosis,&#xD;
             systemic lupus erythamatosus, dermatomyositis/polymyositis, rheumatoid arthritis,&#xD;
             systemic sclerosis, Sjörgen's syndrome, vasculitis/arteritis, Behcet's syndrome,&#xD;
             inflammatory bowel disease, autoimmune thyroiditis, multiple sclerosis, or other&#xD;
             chronic inflammatory disease;&#xD;
&#xD;
          -  Treatment with any other cancer therapy from the time of the first dose of CP-870,893,&#xD;
             except as noted in Section 4.4; 1 Cancer Therapy Evaluation Program, Common&#xD;
             Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS. 31 Mar&#xD;
             2003 (http://ctep.cancer.gov).&#xD;
&#xD;
          -  History of congestive heart failure, stroke, or myocardial infarction;&#xD;
&#xD;
          -  Hereditary or acquired coagulopathies (e.g. hemophilia, von Willebrand's disease,&#xD;
             cancer-associated DIC);&#xD;
&#xD;
          -  Brain metastases.&#xD;
&#xD;
          -  Patient having reproductive potential who is not using an effective method of birth&#xD;
             control or who is pregnant or breastfeeding or has a positive (urine or serum)&#xD;
             pregnancy test at baseline;&#xD;
&#xD;
          -  Known sensitivity to immunomodulating agents or monoclonal antibodies;&#xD;
&#xD;
          -  Alcohol abuse or illicit drug use within 12 months of enrollment;&#xD;
&#xD;
          -  History of serum creatinine ≥2 mg/dL for any duration and for any reason;&#xD;
&#xD;
          -  Urine dipstick 1+ or more positive for blood (other than menstruating females) or 2+&#xD;
             or more positive for protein;&#xD;
&#xD;
          -  Positive HAHA antibody titer in response to treatment with first dose of CP-870,893&#xD;
             (as determined by Pfizer)&#xD;
&#xD;
          -  Clinically significant presence of granular or cellular casts in centrifuged urine&#xD;
             sediment;&#xD;
&#xD;
          -  Renal carcinoma or renal metastases;&#xD;
&#xD;
          -  Partial or complete nephrectomy;&#xD;
&#xD;
          -  History of dialysis (peritoneal or hemodialysis);&#xD;
&#xD;
          -  Prior treatment with Amphotericin B or cisplatin;&#xD;
&#xD;
          -  History of insulin-dependent diabetes for greater than 5 years;&#xD;
&#xD;
          -  Concomitant treatment with systemic corticosteroids or treatment with systemic&#xD;
             corticosteroids within 4 weeks of baseline;&#xD;
&#xD;
          -  Concomitant treatment with anticoagulants, such as coumadin or heparin, except to&#xD;
             maintain patency of in-dwelling catheters;&#xD;
&#xD;
          -  Prior allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to study drug (e.g., rituximab or immunoglobulin G);&#xD;
&#xD;
          -  Ongoing or active infection;&#xD;
&#xD;
          -  Required the use of systemic antibiotics or antifungals for ongoing or recurrent&#xD;
             infections. Topical use of antibiotics or antifungals is allowed;&#xD;
&#xD;
          -  Other uncontrolled concurrent illness that would preclude study participation; or&#xD;
             Psychiatric illness or social situation that would preclude study participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Vonderheide, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>June 4, 2014</study_first_submitted>
  <study_first_submitted_qc>June 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2014</study_first_posted>
  <last_update_submitted>August 15, 2018</last_update_submitted>
  <last_update_submitted_qc>August 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Subjects with Clinical Benefit After a Single Infusion of CP - 870, 893</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

